Epigenetic Therapy in a Rare Ovarian Cancer — A Double-Edged Sword
New England Journal of Medicine · 2024
DOI: 10.1056/nejmc2407971 ↗Kurz gefasst
Fallbericht in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Charles Hsu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY gounderm@mskcc.org. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Ovarian Neoplasms, Rare Diseases, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
A woman with a rare ovarian tumor driven by EZH2 activity responded to tazemetostat, an EZH2 inhibitor, but T-cell acute lymphoblastic leukemia later developed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, New York, NY gounderm@mskcc.org.
ORCID-Profile: Charles Hsu
Zitieren
APA
Hsu, C., Konner, J. A., & Gounder, M. M. (2024). Epigenetic Therapy in a Rare Ovarian Cancer — A Double-Edged Sword. New England Journal of Medicine. https://doi.org/10.1056/nejmc2407971
Vancouver
Hsu C, Konner JA, Gounder MM. Epigenetic Therapy in a Rare Ovarian Cancer — A Double-Edged Sword. New England Journal of Medicine. 2024. doi:10.1056/nejmc2407971
BibTeX
@article{Hsu2024,
author = {Hsu, Charles and Konner, Jason A and Gounder, Mrinal M},
title = {Epigenetic Therapy in a Rare Ovarian Cancer — A Double-Edged Sword},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejmc2407971}
}
EUVIMED